{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:56Z","timestamp":1791357296370,"version":"4.3.1"},"reference-count":155,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaip.2017.01.025","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T05:31:17Z","timestamp":1493962277000},"page":"547-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"title":["Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice"],"prefix":"10.1016","volume":"5","author":[{"given":"Jonathan Grant","family":"Peter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rannakoe","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sipho","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Risma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Konvinse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2017.01.025_bib1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.drudis.2014.03.018","article-title":"An overview of FDA-approved new molecular entities: 1827-2013","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jaip.2017.01.025_bib2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2017.01.025_bib3","doi-asserted-by":"crossref","first-page":"e24061","DOI":"10.1371\/journal.pone.0024061","article-title":"Adverse drug reactions in children\u2014a systematic review","volume":"7","author":"Smyth","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2017.01.025_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjd.14492","article-title":"Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons","volume":"175","author":"Lehloenya","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bcp.12749","article-title":"Classifying ADRs\u2013does dose matter?","volume":"81","author":"Phillips","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2017.01.025_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335612","article-title":"Epidemiology of cutaneous adverse drug reactions","volume":"97","author":"Mockenhaupt","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2230.2010.03922.x","article-title":"Cutaneous adverse drug reactions in a hospital-based Chinese population","volume":"36","author":"Huang","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-12-7","article-title":"Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria","volume":"12","author":"Eluwa","year":"2012","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.jaip.2017.01.025_bib9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199306103282304","article-title":"Cutaneous disease and drug reactions in HIV infection","volume":"328","author":"Coopman","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib10","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/DDDT.S71736","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China","volume":"8","author":"Sun","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/ijd.12118","article-title":"Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study","volume":"53","author":"Su","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.det.2013.11.004","article-title":"Clinical presentations of severe cutaneous drug reactions in HIV-infected Africans","volume":"32","author":"Lehloenya","year":"2014","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaip.2017.01.025_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12788\/j.sder.0057","article-title":"Epidemiology of severe drug hypersensitivity","volume":"33","author":"Dodiuk-Gad","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaip.2017.01.025_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A\u00a0systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2017.01.025_bib15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-4632.2010.04481.x","article-title":"Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia","volume":"49","author":"Ding","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2230.2006.02185.x","article-title":"Epidemiological study of severe cutaneous adverse drug reactions in a city district of China","volume":"31","author":"Li","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.01.025_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A\u00a0three-year-analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2017.01.025_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5501\/wjv.v4.i3.198","article-title":"Pharmacogenetics as a tool to tailor antiretroviral therapy: a review","volume":"4","author":"Aceti","year":"2015","journal-title":"World J Virol"},{"key":"10.1016\/j.jaip.2017.01.025_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen","year":"2014","journal-title":"Anti-cancer Drugs"},{"key":"10.1016\/j.jaip.2017.01.025_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2133.2011.10705.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature","volume":"166","author":"Ziemer","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib31","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib32","first-page":"13","article-title":"Lichenoid drug eruption","volume":"15","author":"Brauer","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaip.2017.01.025_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib35","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib36","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib37","first-page":"1056","article-title":"Stevens-Johnson syndrome, toxic epidermal necrolysis and phenytoin: factors linked to a higher risk [in Spanish]","volume":"38","author":"Gomez-Criado","year":"2004","journal-title":"Rev Neurol"},{"key":"10.1016\/j.jaip.2017.01.025_bib38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","article-title":"Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features","volume":"70","author":"Cho","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archderm.1984.01650400102024","article-title":"Fixed drug eruption: a brief review","volume":"120","author":"Korkij","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-4362.1988.tb04923.x","article-title":"Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis","volume":"27","author":"Baird","year":"1988","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jaip.2017.01.025_bib44","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib45","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis: analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib46","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2010.09967.x","article-title":"The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases","volume":"163","author":"Halevy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib47","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1086\/599615","article-title":"Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes","volume":"49","author":"Apisarnthanarak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2017.01.025_bib48","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1651-2227.1986.tb10324.x","article-title":"Serum-sickness-like disease is a common cause of acute arthritis in children","volume":"75","author":"Kunnamo","year":"1986","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.jaip.2017.01.025_bib49","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib50","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJM198411293112204","article-title":"A\u00a0prospective clinical and immunologic analysis of patients with serum sickness","volume":"311","author":"Lawley","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0190-9622(85)70182-X","article-title":"Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin","volume":"13","author":"Bielory","year":"1985","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00431-012-1926-y","article-title":"Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions","volume":"172","author":"Zhang","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaip.2017.01.025_bib53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1345\/aph.1A124","article-title":"Cutaneous and systemic manifestations of drug-induced vasculitis","volume":"36","author":"ten Holder","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2017.01.025_bib54","series-title":"Advances in the Etiology, Pathogenesis and Pathology of Vasculitis","first-page":"275","article-title":"Drug-induced vasculitis","author":"Radi\u0107","year":"2011"},{"key":"10.1016\/j.jaip.2017.01.025_bib55","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib56","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib57","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2017.01.025_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2017.01.025_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0091-6749(00)90191-X","article-title":"Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response","volume":"105","author":"Leyva","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib61","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T\u00a0cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib62","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1172\/JCI119505","article-title":"Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T\u00a0cell clones","volume":"100","author":"Schnyder","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2017.01.025_bib64","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2017.01.025_bib65","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1067\/mai.2003.1507","article-title":"Characterization of drug-specific T cells in lamotrigine hypersensitivity","volume":"111","author":"Naisbitt","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib66","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2133\/dmpk.DMPK-11-RV-116","article-title":"A\u00a0recent update of pharmacogenomics in drug-induced severe skin reactions","volume":"27","author":"Wei","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jaip.2017.01.025_bib67","doi-asserted-by":"crossref","first-page":"e0117160","DOI":"10.1371\/journal.pone.0117160","article-title":"Abacavir-reactive memory T cells are present in drug naive individuals","volume":"10","author":"Lucas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2017.01.025_bib68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1398-9995.57.s72.15.x","article-title":"Deciphering the immune pathomechanism of cutaneous drug reactions","volume":"57","author":"Pichler","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib69","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2332\/allergolint.55.17","article-title":"Pharmacological interaction of drugs with immune receptors: the p-i concept","volume":"55","author":"Pichler","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2017.01.025_bib71","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2017.01.025_bib72","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2017.01.025_bib73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib74","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2017.01.025_bib75","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib76","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib77","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/jid.2015.165","article-title":"Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions","volume":"135","author":"Chung","year":"2015","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib78","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/ced.12246","article-title":"Increased ratio of FoxP3+ regulatory T cells\/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms","volume":"39","author":"Morito","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8421-3","article-title":"Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review","volume":"49","author":"Shiohara","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib80","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib81","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib82","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000335624","article-title":"Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management","volume":"97","author":"Shiohara","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib83","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib84","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib85","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2017.01.025_bib86","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib87","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0b013e3282f7cb60","article-title":"A\u00a0review of drug patch testing and implications for HIV clinicians","volume":"22","author":"Shear","year":"2008","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib88","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/00002030-200211080-00017","article-title":"Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir","volume":"16","author":"Phillips","year":"2002","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib89","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib90","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-3083.2011.04418.x","article-title":"A\u00a0patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions","volume":"27","author":"Lin","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2017.01.025_bib91","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib92","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2133.2008.08975.x","article-title":"Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions","volume":"160","author":"Waton","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib93","first-page":"15","article-title":"Testing for drug hypersensitivity syndromes","volume":"34","author":"Rive","year":"2013","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jaip.2017.01.025_bib94","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/QAD.0000000000000345","article-title":"HLA class I restricted CD8+ and class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity","volume":"28","author":"Keane","year":"2014","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib95","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12145","article-title":"In\u00a0vitro drug causality assessment in Stevens-Johnson syndrome\u2014alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib96","first-page":"S1","article-title":"Allergy diagnostic testing: an updated practice parameter","volume":"100","author":"Bernstein","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib97","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib98","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/all.12774","article-title":"Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group","volume":"71","author":"Gomes","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib99","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.det.2006.06.008","article-title":"Adverse cutaneous drug eruptions and HIV: a clinician's global perspective","volume":"24","author":"Todd","year":"2006","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaip.2017.01.025_bib100","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.5588\/ijtld.10.0698","article-title":"Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions","volume":"15","author":"Lehloenya","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jaip.2017.01.025_bib101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","article-title":"Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response","volume":"136","author":"White","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib102","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib103","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.103","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing","volume":"94","author":"Leckband","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib104","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12016-014-8418-y","article-title":"Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review","volume":"48","author":"Yip","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib105","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib106","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2017.01.025_bib107","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jaip.2017.01.025_bib108","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev-med-050913-022745","article-title":"T\u00a0cell-mediated hypersensitivity reactions to drugs","volume":"66","author":"Pavlos","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaip.2017.01.025_bib109","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1038\/ncomms8633","article-title":"Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study","volume":"6","author":"Chen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2017.01.025_bib110","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cpt.309","article-title":"HLA-B*38:02:01 predicts carbimazole\/methimazole-induced agranulocytosis","volume":"99","author":"Cheung","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2017.01.025_bib111","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(16)00113-3","article-title":"Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population","volume":"4","author":"Hallberg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jaip.2017.01.025_bib112","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2017.01.025_bib113","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1212\/WNL.0000000000001034","article-title":"Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions","volume":"83","author":"Chen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jaip.2017.01.025_bib114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib115","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jaad.2013.12.025","article-title":"HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4(+) T cells","volume":"70","author":"Yang","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib116","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2009.02180.x","article-title":"In\u00a0vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases","volume":"65","author":"Zawodniak","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib117","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2332\/allergolint.10-RAI-0261","article-title":"Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Chung","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2017.01.025_bib118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1398-9995.2007.01516.x","article-title":"CD69 upregulation on T cells as an in\u00a0vitro marker for delayed-type drug hypersensitivity","volume":"63","author":"Beeler","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib119","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaip.2017.01.025_bib120","first-page":"278","article-title":"Drug eruptions: approaching the diagnosis of drug-induced skin diseases","volume":"2","author":"Nigen","year":"2003","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaip.2017.01.025_bib121","first-page":"CD005646","article-title":"Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients with previous history of hypersensitivity to cotrimoxazole","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2017.01.025_bib122","first-page":"295","article-title":"Allopurinol desensitization: a fast or slow protocol?","volume":"25","author":"Soares","year":"2015","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib123","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1016\/j.burns.2004.08.004","article-title":"Pain management","volume":"30","author":"Patterson","year":"2004","journal-title":"Burns"},{"key":"10.1016\/j.jaip.2017.01.025_bib124","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","article-title":"Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center","volume":"76","author":"Lee","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib125","first-page":"124","article-title":"Management of Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"20","author":"Lehloenya","year":"2007","journal-title":"Curr Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.01.025_bib126","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1346-8138.2005.tb00782.x","article-title":"Heterotopic ossification related to toxic epidermal necrolysis in a patient with Behcet's disease","volume":"32","author":"Samanci","year":"2005","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib127","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2133.1994.tb03396.x","article-title":"Silicone gel treatment of extensive hypertrophic scarring following toxic epidermal necrolysis","volume":"130","author":"Kavanagh","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.109.1.74","article-title":"Long-term consequences of toxic epidermal necrolysis in children","volume":"109","author":"Sheridan","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2017.01.025_bib129","first-page":"540","article-title":"Eruptive nevus in the course of Lyell syndrome [in French]","volume":"122","author":"Jullien","year":"1995","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaip.2017.01.025_bib130","first-page":"157","article-title":"Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.burns.2015.03.012","article-title":"Complications of Stevens-Johnson syndrome beyond the eye and skin","volume":"42","author":"Saeed","year":"2016","journal-title":"Burns"},{"key":"10.1016\/j.jaip.2017.01.025_bib132","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/archdermatol.2009.233","article-title":"Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis","volume":"145","author":"Gaultier","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib133","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0305-4179(97)00107-1","article-title":"Toxic epidermal necrolysis in a burn patient complicated by acute pancreatitis","volume":"24","author":"Coetzer","year":"1998","journal-title":"Burns"},{"key":"10.1016\/j.jaip.2017.01.025_bib134","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/BF02048370","article-title":"Toxic epidermal necrolysis\u2013an unusual cause of colonic perforation. Report of a case","volume":"36","author":"Carter","year":"1993","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jaip.2017.01.025_bib135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02343438","article-title":"Esophageal stricture secondary to drug-induced toxic epidermal necrolysis","volume":"14","author":"Herman","year":"1984","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jaip.2017.01.025_bib136","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/GOX.0b013e3182980067","article-title":"A\u00a0case of microstomia subsequent to toxic epidermal necrolysis surgically treated by simple technique","volume":"1","author":"Mashiko","year":"2013","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.jaip.2017.01.025_bib137","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archotol.124.12.1375","article-title":"Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis","volume":"124","author":"Barrera","year":"1998","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2017.01.025_bib138","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/LGT.0b013e3181ddf5da","article-title":"Vaginal stenosis after toxic epidermal necrolysis","volume":"14","author":"Rowan","year":"2010","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.jaip.2017.01.025_bib139","first-page":"815","article-title":"Drug-induced toxic epidermal necrolysis with involvement of the intestinal and respiratory tract: a case report [in German]","volume":"51","author":"Jackel","year":"2002","journal-title":"Anaesthesist"},{"key":"10.1016\/j.jaip.2017.01.025_bib140","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1346-8138.2006.00142.x","article-title":"Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro\/SS-A and a review of the published work","volume":"33","author":"Kamada","year":"2006","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-7022-4-S3-P95","article-title":"Incidence of anxiety and depression in a predominantly HIV-infected population with severe adverse drug reactions","volume":"4","author":"Zitha","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2017.01.025_bib142","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ijd.12331","article-title":"Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients","volume":"54","author":"Sultan","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib143","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib144","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib145","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjd.13375","article-title":"Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms","volume":"172","author":"Lew","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib146","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1093\/jac\/dks225","article-title":"Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy","volume":"67","author":"Lehloenya","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2017.01.025_bib147","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib148","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaip.2013.11.008","article-title":"Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms","volume":"2","author":"Galvao","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.01.025_bib149","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib150","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.148.4.dlt120002-c","article-title":"Poor benefit\/risk balance of intravenous immunoglobulins in DRESS","volume":"148","author":"Joly","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib151","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2230.2010.03967.x","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking","volume":"36","author":"Walsh","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib152","first-page":"322","article-title":"Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007-2012","volume":"103","author":"Dube","year":"2013","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.jaip.2017.01.025_bib153","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jaad.2005.09.021","article-title":"Toxic epidermal necrolysis in a mother and fetus","volume":"55","author":"Rodriguez","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.01.025_bib154","doi-asserted-by":"crossref","first-page":"e0135501","DOI":"10.1371\/journal.pone.0135501","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women","volume":"10","author":"Knight","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2017.01.025_bib155","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/BCR.0b013e3181eed441","article-title":"Toxic epidermal necrolysis in pregnancy: case report and review of the literature","volume":"31","author":"Struck","year":"2010","journal-title":"J\u00a0Burn Care Res"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817300466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817300466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:11:52Z","timestamp":1761973912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219817300466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2213219817300466"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2017.01.025","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727591105.793576488","asserted-by":"object"}]},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2017.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}